These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578 [TBL] [Abstract][Full Text] [Related]
3. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA; Peters SL Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946 [TBL] [Abstract][Full Text] [Related]
4. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. Ollivier JP; Christen MO J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226 [TBL] [Abstract][Full Text] [Related]
5. Moxonidine: a new antiadrenergic antihypertensive agent. Prichard BN; Graham BR; Owens CW J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098 [TBL] [Abstract][Full Text] [Related]
6. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Prichard BN; Owens CW; Graham BR J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737 [TBL] [Abstract][Full Text] [Related]
7. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Prichard BN; Graham BR Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201 [TBL] [Abstract][Full Text] [Related]
8. Moxonidine: a review of safety and tolerability after seven years of clinical experience. Schachter M J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097 [TBL] [Abstract][Full Text] [Related]
9. Why imidazoline receptor modulator in the treatment of hypertension? Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385 [TBL] [Abstract][Full Text] [Related]
10. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221 [TBL] [Abstract][Full Text] [Related]
11. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension? van Zwieten PA Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014 [TBL] [Abstract][Full Text] [Related]
12. Effective antihypertensive therapy: blood pressure control with moxonidine. Prichard BN; Graham BR J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298 [TBL] [Abstract][Full Text] [Related]
13. Pharmacology of moxonidine, an I1-imidazoline receptor agonist. Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297 [TBL] [Abstract][Full Text] [Related]
14. The use of moxonidine in the treatment of hypertension. Prichard BN; Graham BR J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986 [TBL] [Abstract][Full Text] [Related]
15. Moxonidine: some controversy. Doggrell SA Expert Opin Pharmacother; 2001 Feb; 2(2):337-50. PubMed ID: 11336590 [TBL] [Abstract][Full Text] [Related]